Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Two Modified-Release Methylphenidate Brands in Children with ADHD
NCT00254878Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Novartis. Primary endpoints: Attention at 4.5 hours and Deportment at 4.5 hours. Started Oct 2005; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00254878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254878.